Drug discovery: selecting the optimal approach.

The target-based drug discovery approach has for the past 10-15 years been the dominating drug discovery paradigm. However, within the past few years, the commercial value of novel targets in licensing deals has fallen dramatically, reflecting that the probability of reaching a clinical drug candidate for a novel target is very low. This has naturally led to questions regarding the success of target-based drug discovery and, more importantly, a search for alternatives. This paper evaluates the strengths and limitations of the main drug discovery approaches, and proposes a novel approach that could offer advantages for the identification of disease-modifying treatments.

[1]  Jürgen Drews,et al.  Innovation Deficit in the Pharmaceutical Industry , 1996 .

[2]  Stephan Heyse,et al.  From targets to leads: the importance of advanced data analysis for decision support in drug discovery. , 2005, Current opinion in drug discovery & development.

[3]  F. Sams-Dodd,et al.  Optimizing the discovery organization for innovation. , 2005, Drug discovery today.

[4]  H. Meltzer,et al.  Lithium differs from anticonvulsant mood stabilizers in prefrontal cortical and accumbal dopamine release: Role of 5-HT1A receptor agonism , 2005, Brain Research.

[5]  E. Kunkel.  Systems biology in drug discovery , 2004, Nature Biotechnology.

[6]  M. Rosenkilde,et al.  High content screening for G protein-coupled receptors using cell-based protein translocation assays. , 2005, Combinatorial chemistry & high throughput screening.

[7]  P. Shepherd,et al.  Human cell systems for drug discovery. , 2003, Current opinion in drug discovery & development.

[8]  W. Bailey,et al.  Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease , 2004, Expert opinion on pharmacotherapy.

[9]  M. Véniant,et al.  Leptin: from animals to humans. , 2003, Current pharmaceutical design.

[10]  E. Masliah,et al.  Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer's Disease , 2005, Science.

[11]  Gareth P. Williams,et al.  Advances in high throughput screening. , 2004, Drug discovery today.

[12]  G. Superti-Furga,et al.  Rediscovering the sweet spot in drug discovery. , 2003, Drug discovery today.

[13]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[14]  J. Trojanowski,et al.  Tau and α-Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam , 2002 .

[15]  Walter H. Moos,et al.  Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies , 1995 .

[16]  F. Sams-Dodd.  Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[17]  H. Arai,et al.  [A proposal for diagnostic and clinical assessment criteria for Alzheimer's disease]. , 2005, Rinsho shinkeigaku = Clinical neurology.

[18]  A. Nadin,et al.  Selected Non-steroidal Anti-inflammatory Drugs and Their Derivatives Target γ-Secretase at a Novel Site , 2004, Journal of Biological Chemistry.

[19]  J. Hardy,et al.  Genome-wide analysis of the parkinsonism-dementia complex of Guam. , 2004, Archives of neurology.

[20]  W. Kilarski,et al.  An ex vivo model for functional studies of myofibroblasts , 2005, Laboratory Investigation.

[21]  David F. Horrobin,et al.  Modern biomedical research: an internally self-consistent universe with little contact with medical reality? , 2003, Nature Reviews Drug Discovery.

[22]  L. Zon,et al.  The zebrafish: a new model of T-cell and thymic development , 2005, Nature Reviews Immunology.

[23]  F. Sams-Dodd,et al.  Strategies to optimize the validity of disease models in the drug discovery process. , 2006, Drug discovery today.

[24]  Yang Li,et al.  Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing. , 2003, Chemistry & biology.

[25]  E. Butcher.  Can cell systems biology rescue drug discovery? , 2005, Nature Reviews Drug Discovery.

[26]  M. Vaswani,et al.  Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.